Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNZMH6)

• Drug Name: 3-iodotyrosine Drug Info
• Synonyms: 2-amino-3-(4-hydroxy-3-iodophenyl)propanoic acid; 3078-39-5; 3-Iodo-DL-tyrosine; C9H10INO3; 3-iodo-l-tyr; AC1Q4PGG; ACMC-209og3; SCHEMBL159411; AC1L1M60; GTPL5117; CTK7I4445; UQTZMGFTRHFAAM-UHFFFAOYSA-N; MolPort-006-167-934; NSC210787; AKOS022187633; S(-)-3-Iodo-4-hydroxy- phenylamine; TRA0009499; MCULE-7084802066; AN-8912; NSC-210787; FCH1320103; SC-11023; KB-32311; AX8285033; Z5788; 2-Amino-3-(3-iodo-4-hydroxyphenyl)propionic acid; 2-Amino-3-(4-hydroxy-3-iodophenyl)propionic acid; 2-amino-3-(4-hydroxy-3-iodo-phenyl)propanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 439744
  ChEBI ID: CHEBI:27847
  CAS Number: CAS 70-78-0
  TTD Drug ID: DMNZMH6

Molecule-Related Drug Atlas

Drug(s) Targeting Tyrosine 3-monooxygenase (TH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Phenylalanine	DMQXI9F	Malnutrition	5B50-5B71	Approved	[4]
L-Tyrosine	DM9O8DT	Malnutrition	5B50-5B71	Approved	[5]
Tetrahydrobiopterin	DMINZ4W	Malnutrition	5B50-5B71	Approved	[6]
Metyrosine	DMBYCU0	Pheochromocytoma	5A75	Approved	[7]
L1-79	DMLHPVW	Autism spectrum disorder	6A02	Phase 2	[8]
ProSavin	DMJ42E6	Parkinson disease	8A00.0	Phase 1/2	[9]
OXB-102	DMXF9DM	Parkinson disease	8A00.0	Phase 1/2	[10]
7,8-dihydrobiopterin	DMQU4XM	Discovery agent	N.A.	Investigative	[11]
alpha-propyldopacetamide	DMQKMX3	Discovery agent	N.A.	Investigative	[2]
Meta-Tyrosine	DM0748C	Discovery agent	N.A.	Investigative	[11]

Drug(s) Affected By Iodotyrosine deiodinase 1 (IYD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[12]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[12]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[13]
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[14]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[15]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[16]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[17]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[14]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[18]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tyrosine 3-monooxygenase (TH)	TTUHP71	TY3H_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Iodotyrosine deiodinase 1 (IYD)	OT8BQWTE	IYD1_HUMAN	Regulation of Drug Effects	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5117).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).
• [3] In vitro screening for chemical inhibition of the iodide recycling enzyme, iodotyrosine deiodinase. Toxicol In Vitro. 2021 Mar;71:105073. doi: 10.1016/j.tiv.2020.105073. Epub 2020 Dec 29.
• [4] Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67.
• [5] Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5.
• [6] Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
• [7] Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
• [8] Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981.
• [9] Clinical pipeline report, company report or official report of Oxford BioMedica.
• [10] Clinical pipeline report, company report or official report of Oxford BioMedica.
• [11] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [12] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [13] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [14] Structure-activity relationships of 44 halogenated compounds for iodotyrosine deiodinase-inhibitory activity. Toxicology. 2013 Dec 6;314(1):22-9. doi: 10.1016/j.tox.2013.08.017. Epub 2013 Sep 3.
• [15] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [16] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [17] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [18] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [19] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.